Navigation Links
Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Date:5/5/2008

lar Biology and Genetics from the University of Guelph and completed a three-year post-doctoral training program at the University of Michigan. He joined Lorus through the merger with GeneSense Technologies Inc. in 1999, where he was a Research Scientist involved in the GeneSense oligonucleotide therapeutics program. He has authored many scientific publications and is also an author of numerous patents and conference proceedings.

"I am delighted to promote these two experienced professionals to our senior management team", said Dr. Aiping Young, Lorus' President and CEO. "Their skills and knowledge will allow us to progress our novel anticancer drugs towards commercialization and seize emerging opportunities to accelerate the growth of our business."

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events an
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... DIEGO, California, USA (PRWEB) August 28, 2014 ... the Department of Physics and Optical Science and Director ... the University of North Carolina at Charlotte, and co-founder ... been elected to serve as the 2015 Vice President ... , SPIE 2014 President Philip Stahl announced recent election ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... YORK , Aug. 28, ... that a new market research ... catalogue: Whole Exome ... Kits (Library Preparation, Target Enrichment), ... (Sequencing by Synthesis), by Application ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... (NYSE: CRY ),a biomaterials, medical device and tissue ... will be released on,Thursday, July 31, 2008. The Company ... a.m. Eastern Time, July 31, 2008, to discuss the,results, ... Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
... management system at its Gardner, Mass., facility, focusing on continuous process ... ... July 15, 2008 -- New England Peptide, LLC (NEP), is developing ... on continuous process improvement and customer satisfaction., , ,The program is ...
... AMSTERDAM, The Netherlands, July 15 Amsterdam,Molecular Therapeutics ... human gene,therapy, today announced the start of a ... Tennessee, USA, on the development,of a gene therapy ... will,receive the exclusive commercial rights to the final ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration 2New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4
(Date:8/31/2014)... French . ... the prestigious Nature Neuroscience journal by, Sylvain Williams, ... Douglas Mental Health University Institute and McGill University, opens the ... mechanisms controlling memory as well of the role of an ... subiculum. , In 2009, they developed a unique approach ...
(Date:8/29/2014)... University of Texas Medical Branch at Galveston has gone on ... completely protect monkeys against a lethal dose of Ebola virus ... the disease is severe. , Thomas Geisbert, professor of microbiology ... discussing advances in Ebola treatment research. The filoviruses known as ... of pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... news release is available in German . ... chemical signals between organisms is considered the oldest form ... interactions between conspecifics, for example, the sexual attraction between ... social responses and to coordinate reproductive behavior in males ... the University of the Algarve in Faro, Portugal, and ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3
... host the first-ever Central Gulf of Mexico Hurricane Conference ... meeting will bring together 300-500 experts and officials from ... local public safety personnel, forecasters, university officials to ... 1 start of the 2010 Atlantic hurricane season. ...
... This release is available in German . ... last interglacial epoch, around 115,000 years ago, there were ... slow transition from the Eemian Interglacial to the Weichselian ... trends with possibly at least two warming events. This ...
... people worldwide. It is the most common form of age-related ... is no cure, and the available drugs only help to ... the characteristic changes in the brains of Alzheimer,s patients is ... for curing or at least slowing the disease lies in ...
Cached Biology News:2010 Central Gulf of Mexico Hurricane Conference, Baton Rouge, March 16-17 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2The sea squirt offers hope for Alzheimer's sufferers 2
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
...
... With increasing age, the autofluorescent ... of many cell types, including neurons. ... complicate the use of fluorescence microscopy ... of its broad excitation and emission ...
Biology Products: